Satellos Bioscience (NASDAQ:MSLE), a biotechnology company focused on developing small-molecule therapies that modulate muscle stem cell regeneration, reported its full-year 2025 financial results and provided updates on recent corporate and clinical milestones.
The company closed a US$57.2 million equity financing and began trading on the Nasdaq Capital Market on February 6, 2026.
As of December 31, 2025, Satellos held $27.7 million in cash and cash equivalents.
The company expects its cash position, bolstered by the subsequent financing, to provide a runway through 2027.
For the full year 2025, Satellos reported a net loss of $24.9 million.
In 2025, the company initiated two Phase 2 clinical trials evaluating SAT-3247: the BASECAMP trial in pediatric patients and the TRAILHEAD trial in adult patients with DMD.
Satellos also presented clinical and biomarker data from earlier studies that demonstrated functional gains in patients and supported the use of a validated Regenerative Index as a potential measure of treatment effect.